Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 425 Merger Prospectus

SEC Filings

Acasti Pharma Inc.

CIK: 1444192 Ticker: ACST

View differences made from one to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 425 Merger Prospectus to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools
Ticker: ACST
CIK: 1444192
Form Type: 425 Merger Prospectus
Accession Number: 0001171843-21-005501
Submitted to the SEC: Wed Aug 04 2021 5:03:22 PM EST
Accepted by the SEC: Wed Aug 04 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0001171843-21-005501.htm